Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Dynamics of device innovation: implications for assessing value.

Gelijns AC, Russo MJ, Hong KN, Brown LD, Ascheim DD, Moskowitz AJ.

Int J Technol Assess Health Care. 2013 Oct;29(4):365-73. doi: 10.1017/S0266462313000561.

PMID:
24290326
2.

The clinical and cost-effectiveness of left ventricular assist devices for end-stage heart failure: a systematic review and economic evaluation.

Clegg AJ, Scott DA, Loveman E, Colquitt J, Hutchinson J, Royle P, Bryant J.

Health Technol Assess. 2005 Nov;9(45):1-132, iii-iv. Review.

3.

Special report: cost-effectiveness of left-ventricular assist devices as destination therapy for end-stage heart failure.

[No authors listed]

Technol Eval Cent Assess Program Exec Summ. 2004 Apr;19(2):1. No abstract available.

PMID:
15314825
4.

Left ventricular assist devices: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2004;4(3):1-69. Epub 2004 Mar 1.

5.

Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model.

Sutcliffe P, Connock M, Pulikottil-Jacob R, Kandala NB, Suri G, Gurung T, Grove A, Shyangdan D, Briscoe S, Maheswaran H, Clarke A.

Health Technol Assess. 2013 Nov;17(53):1-499, v-vi. doi: 10.3310/hta17530. Review.

6.

Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy.

Rogers JG, Bostic RR, Tong KB, Adamson R, Russo M, Slaughter MS.

Circ Heart Fail. 2012 Jan;5(1):10-6. doi: 10.1161/CIRCHEARTFAILURE.111.962951. Epub 2011 Nov 3.

7.

Cost-effectiveness of continuous-flow left ventricular assist devices.

Neyt M, Van den Bruel A, Smit Y, De Jonge N, Erasmus M, Van Dijk D, Vlayen J.

Int J Technol Assess Health Care. 2013 Jul;29(3):254-60. doi: 10.1017/S0266462313000238. Epub 2013 Jun 14.

PMID:
23763844
8.

Left ventricular assist device as destination therapy: application of the payment-by-results approach for the device reimbursement.

Messori A, Trippoli S, Bonacchi M, Sani G.

J Thorac Cardiovasc Surg. 2009 Aug;138(2):480-5. doi: 10.1016/j.jtcvs.2009.02.016. Epub 2009 May 5.

PMID:
19619799
9.

Implantable ventricular assist devices: is it time to introduce them in Canada?

McGregor M.

Can J Cardiol. 2000 May;16(5):629-40.

PMID:
10833542
10.

Left ventricular assist devices as destination therapy: a new look at survival.

Park SJ, Tector A, Piccioni W, Raines E, Gelijns A, Moskowitz A, Rose E, Holman W, Furukawa S, Frazier OH, Dembitsky W.

J Thorac Cardiovasc Surg. 2005 Jan;129(1):9-17. Erratum in: J Thorac Cardiovasc Surg. 2005 Jun;129(6):1464.

PMID:
15632819
11.

Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support).

Starling RC, Naka Y, Boyle AJ, Gonzalez-Stawinski G, John R, Jorde U, Russell SD, Conte JV, Aaronson KD, McGee EC Jr, Cotts WG, DeNofrio D, Pham DT, Farrar DJ, Pagani FD.

J Am Coll Cardiol. 2011 May 10;57(19):1890-8. doi: 10.1016/j.jacc.2010.10.062. Erratum in: J Am Coll Cardiol. 2011 Nov 8;58(20):2142.

12.
13.

Orthotopic heart transplant versus left ventricular assist device: a national comparison of cost and survival.

Mulloy DP, Bhamidipati CM, Stone ML, Ailawadi G, Kron IL, Kern JA.

J Thorac Cardiovasc Surg. 2013 Feb;145(2):566-73; discussion 573-4. doi: 10.1016/j.jtcvs.2012.10.034. Epub 2012 Dec 13.

14.

The cost-utility of left ventricular assist devices for end-stage heart failure patients ineligible for cardiac transplantation: a systematic review and critical appraisal of economic evaluations.

Neyt M, Van den Bruel A, Smit Y, De Jonge N, Vlayen J.

Ann Cardiothorac Surg. 2014 Sep;3(5):439-49. doi: 10.3978/j.issn.2225-319X.2014.09.02. Review.

15.

Assessing low volume, high cost, potentially life saving surgical interventions: how and when? Left ventricular assist devices (LVADs) as a case study.

Robert G, Caine N, Sharples LD, Buxton MJ, Large SR, Wallwork J.

J Eval Clin Pract. 1999 Nov;5(4):387-91. Review. No abstract available.

PMID:
10579702
16.

Improving outcomes with long-term "destination" therapy using left ventricular assist devices.

Long JW, Healy AH, Rasmusson BY, Cowley CG, Nelson KE, Kfoury AG, Clayson SE, Reid BB, Moore SA, Blank DU, Renlund DG.

J Thorac Cardiovasc Surg. 2008 Jun;135(6):1353-60; discussion 1360-1. doi: 10.1016/j.jtcvs.2006.09.124.

PMID:
18544385
17.

Progress versus precision: challenges in clinical trial design for left ventricular assist devices.

Parides MK, Moskowitz AJ, Ascheim DD, Rose EA, Gelijns AC.

Ann Thorac Surg. 2006 Sep;82(3):1140-6. Review.

PMID:
16928569
18.

Ethical challenges with the left ventricular assist device as a destination therapy.

Rizzieri AG, Verheijde JL, Rady MY, McGregor JL.

Philos Ethics Humanit Med. 2008 Aug 11;3:20. doi: 10.1186/1747-5341-3-20.

19.

Cost-effectiveness of left ventricular-assist devices in end-stage heart failure.

Hutchinson J, Scott DA, Clegg AJ, Loveman E, Royle P, Bryant J, Colquitt JL.

Expert Rev Cardiovasc Ther. 2008 Feb;6(2):175-85. doi: 10.1586/14779072.6.2.175. Review.

PMID:
18248272
20.

The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk